Testing antibodies in itching after immune therapy
Part of Cancer, Immune system & allergy, Skin clinical trials.
This study checks blood antibodies (BP180 and BP230) in people who develop long-lasting itching after starting immune therapy for cancer. It may help doctors understand why the itching happens and how it relates to autoimmune skin conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently on immune therapy (pembrolizumab, nivolumab, atezolizumab, or durvalumab), or you finished it within the last 6 months
- Your itching (pruritus) has lasted more than 1 month and started after you began immune therapy
- There was no obvious skin rash or skin disease that explains the itching at the time it began
- If you can become pregnant, you must use effective birth control and have a recent negative pregnancy test
- You must sign an informed consent form and be covered by a social security program
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gel called TriCalm Hydrogel to see if it helps reduce itching caused by immunotherapy cancer treatment. If you have itching from your immunotherapy, this study might offer relief.
This study tests whether a psychological therapy called EMDR (which uses eye movements to process difficult memories) can help reduce chronic itching. You may be able to join if you have had moderate to severe itching for a long time and are not on certain other treatments.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
This trial tests if the drug Aprepitant can help relieve itching caused by immunotherapy treatments in people with solid tumors. It is for those whose itching has not responded to standard treatments or started after beginning immunotherapy.
This trial tests if dupilumab (Dupixent) can help adults with long-lasting, severe itching from healed burn scars. It is for people whose itching has not improved with standard treatments like antihistamines.
This early trial tests whether dupilumab can reduce itching in people with certain inherited (genetic) inflammatory skin conditions. It may help by calming skin inflammation that causes ongoing itch and sleep problems.
Hear when a new Patients With Chronic Pruritus for More Than 1 Month Who Have Received Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.